# Public Comments Summary

## Themes

***Public comment adjustments are made through track changes***

* Advocacy:
  + Increased suggestions for advocacy for elected officials
  + Advocacy against Drug Free Workplace laws
* Equity lens *->* ***added paragraph to the background section***
* Access
  + Buprenorphine over-the-counter buprenorphine for competent adults
  + Emphasis on access to harm reduction services across all settings
  + Prioritize comprehensive array of care (physical, behavioral, social needs)
  + Emphasize reference to Hepatitis C report
* Training/Education
  + Antiracism, Stigma and bias training and education for providers and students
  + Overdose prevention and naloxone administration
* Accountability and flexibility of SUDPs to treat SUDs
* Prescribing of MOUD
  + Changes for perinatal individuals (split-dosing)
* Additional resources
* Evaluation
  + Specific indicators of interest, such as patient satisfaction
  + Inclusion of health system improvement measures (treatment penetration, cost effectiveness, broader health outcomes for people who use drugs (QOL measures, satisfaction)
* Payment
  + Recognition that reimbursement for peer support begins after July 2025
  + Lower total cost of care, as may not be able to remove copays/coinsurance due to regulatory barriers from IRS
  + Encourage building partnerships with CBOs to provide mobile vans/in-person outreach
  + Adjustment to statement about refusing to contract with facilities/providers refusing to offer MOUD
* Changes in tables for:
  + Primary care
  + Behavioral health
  + Perinatal providers
  + Emergency department
  + Inpatient settings
  + Syringe service programs
* MOUD section:
  + Additions to buprenorphine, naltrexone and naloxone